InnoCan Pharma Overview
Innocan Pharma is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation. In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales.
Cumulative Funding Raised Over Time ($)
$155KApr 2025
$1.0MAug 2018
$2.4MAug 2023
$3.2MAug 2024
$5.0MDec 2020
$5.4MJan 2025
$7.3MMar 2024
$8.3MMar 2025
$14.9MOct 2021
$18.5MSep 2019
Latest News
growth-positive
Innocan Pharma to Present at the 2025 ThinkEquity Conference
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology industries, announced its participation in the ThinkEquity Conference on October 30, 2025, in New York City. The conference is a platform for institutional investors, analysts, and emerging growth companies to share business updates and explore new market opportunities. Innocan will present its upcoming regulatory milestones in human and animal health, focusing on its LPT-CBD injectable platform for chronic pain management. The companys CEO, Iris Bincovich, COO, Roni Kamhi, and advisory board member Dr. Joseph V. Pergolizzi, Jr., will be presenting. Innocan is known for its innovative CBD-loaded liposome drug delivery platform and a wide range of wellness products.
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
growth-positive
Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan
Innocan Pharma Corporation has announced that its patent for LPT-CBD, a prolonged-release liposome-based formulation encapsulating cannabinoids, has been allowed in Japan. This patent is part of a broader international patent family and follows a previously granted patent in India. The LPT-CBD formulation is designed for sustained release of synthetic CBD into the bloodstream and has shown prolonged pharmacokinetics and pain-relief effects in preclinical studies. The patent allowance in Japan, the worlds third-largest pharmaceutical market, represents a significant milestone for Innocan in advancing LPT-CBD as a non-opioid solution for chronic pain management. The development of LPT-CBD is in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem.
Product StagePartners
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has received allowance for its patent on LPT-CBD, a prolonged-release liposome-based formulation encapsulating cannabinoids, in Japan. This patent, which will be officially granted after administrative processes, strengthens Innocans global intellectual property portfolio. The LPT-CBD formulation is designed for sustained release of synthetic CBD into the bloodstream, offering a non-opioid solution for chronic pain management. Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University, the technology has shown prolonged pharmacokinetics and pain relief effects in preclinical studies. The U.S. FDA has provided positive feedback for advancing LPT-CBD development. Innocan is focused on expanding its patent approvals globally, with Japan being a significant market due to its size.
Product Stage
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has announced its ongoing collaboration with Freedom Farm, a sanctuary for animals with disabilities, to provide pain relief using its LPT-CBD analgesic. This liposomal drug product offers long-acting pain management through a single subcutaneous injection every 6-9 weeks. The treatment has significantly improved the quality of life for animals like Billy and Dror, two goats with severe skeletal deformities, by alleviating pain and restoring mobility. The collaboration highlights Innocans commitment to enhancing animal welfare and showcases the potential of its technology in pain management. The initiative is seen as a positive step towards promoting a compassionate world and advancing non-opioid pain management solutions.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $23.67M |
| Last funding | $155K |
| Stage | Public |
| Rounds | 13 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | innocanpharma.com |
Locations
HaMenofim Street 10, Herzliya, Israel
Photos & Videos
3 item(s)
InnoCan Pharma Business
Business models
B2B2C, B2C, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsCellsHerbalsTags (21)
diabetesdrug-deliverypharmaceuticalstherapeuticscannabispatientstopical-treatmentdermatologypain-reliefpatent-pendingwellnesspharma-companieswomen-healthalzheimers-diseasetreatmentsepilepsyecommercecell-therapymedical-cannabisinhalationcosmeticsGeographic Markets
AsiaUnited StatesEuropeCanadaInnoCan Pharma Financials
$23.67M
Total funding
Undisclosed
Capital raised
$155K
Last funding
Public
Funding stage
13
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$155KApr 2025
$1.0MAug 2018
$2.4MAug 2023
$3.2MAug 2024
$5.0MDec 2020
$5.4MJan 2025
$7.3MMar 2024
$8.3MMar 2025
$14.9MOct 2021
$18.5MSep 2019
Private Equity Funding
PIPE
Apr 2025
$155K
PIPE
Mar 2025
$1M
Tamar Innovest
PIPE
Jan 2025
$443K
PIPE
Aug 2024
$811K
Undisclosed Investor(s)
PIPE
Mar 2024
$1.9M
PIPE
Aug 2023
$1.41M
Undisclosed Investor(s)
PIPE
Oct 2021
$6.6M
Undisclosed Investor(s)
PIPE
Dec 2020
$1.75M
Undisclosed Investor(s)
Undisclosed Round
Sep 2019
$3.55M
Invicta Ventures
Equity crowdfunding
Aug 2018
$850K
PipelBiz
Public Offering / Exit
POEvent
Aug 2021
Undisclosed
POEvent
Jun 2020
Undisclosed
POEvent
Sep 2019
Undisclosed
InnoCan Pharma Lifecycle
Cumulative Funding Raised Over Time
$155KApr 2025
$1.0MAug 2018
$2.4MAug 2023
$3.2MAug 2024
$5.0MDec 2020
$5.4MJan 2025
$7.3MMar 2024
$8.3MMar 2025
$14.9MOct 2021
$18.5MSep 2019
All Events
PIPE
Apr 2025
$155K
PIPE
Mar 2025
$1M
Tamar Innovest
PIPE
Jan 2025
$443K
PIPE
Aug 2024
$811K
Undisclosed Investor(s)
PIPE
Mar 2024
$1.9M
PIPE
Aug 2023
$1.41M
Undisclosed Investor(s)
PIPE
Oct 2021
$6.6M
Undisclosed Investor(s)
PIPE
Dec 2020
$1.75M
Undisclosed Investor(s)
Undisclosed Round
Sep 2019
$3.55M
Invicta Ventures
Equity crowdfunding
Aug 2018
$850K
PipelBiz
POEvent
Aug 2021
Undisclosed
POEvent
Jun 2020
Undisclosed
POEvent
Sep 2019
Undisclosed
InnoCan Pharma News
176 articles
growth-positive
Innocan Pharma to Present at the 2025 ThinkEquity Conference
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology industries, announced its participation in the ThinkEquity Conference on October 30, 2025, in New York City. The conference is a platform for institutional investors, analysts, and emerging growth companies to share business updates and explore new market opportunities. Innocan will present its upcoming regulatory milestones in human and animal health, focusing on its LPT-CBD injectable platform for chronic pain management. The companys CEO, Iris Bincovich, COO, Roni Kamhi, and advisory board member Dr. Joseph V. Pergolizzi, Jr., will be presenting. Innocan is known for its innovative CBD-loaded liposome drug delivery platform and a wide range of wellness products.
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
growth-positive
Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan
Innocan Pharma Corporation has announced that its patent for LPT-CBD, a prolonged-release liposome-based formulation encapsulating cannabinoids, has been allowed in Japan. This patent is part of a broader international patent family and follows a previously granted patent in India. The LPT-CBD formulation is designed for sustained release of synthetic CBD into the bloodstream and has shown prolonged pharmacokinetics and pain-relief effects in preclinical studies. The patent allowance in Japan, the worlds third-largest pharmaceutical market, represents a significant milestone for Innocan in advancing LPT-CBD as a non-opioid solution for chronic pain management. The development of LPT-CBD is in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem.
Product StagePartners
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has received allowance for its patent on LPT-CBD, a prolonged-release liposome-based formulation encapsulating cannabinoids, in Japan. This patent, which will be officially granted after administrative processes, strengthens Innocans global intellectual property portfolio. The LPT-CBD formulation is designed for sustained release of synthetic CBD into the bloodstream, offering a non-opioid solution for chronic pain management. Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University, the technology has shown prolonged pharmacokinetics and pain relief effects in preclinical studies. The U.S. FDA has provided positive feedback for advancing LPT-CBD development. Innocan is focused on expanding its patent approvals globally, with Japan being a significant market due to its size.
Product Stage
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has announced its ongoing collaboration with Freedom Farm, a sanctuary for animals with disabilities, to provide pain relief using its LPT-CBD analgesic. This liposomal drug product offers long-acting pain management through a single subcutaneous injection every 6-9 weeks. The treatment has significantly improved the quality of life for animals like Billy and Dror, two goats with severe skeletal deformities, by alleviating pain and restoring mobility. The collaboration highlights Innocans commitment to enhancing animal welfare and showcases the potential of its technology in pain management. The initiative is seen as a positive step towards promoting a compassionate world and advancing non-opioid pain management solutions.
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation has announced its ongoing collaboration with Freedom Farm, a sanctuary for animals with physical disabilities. The collaboration involves the use of Innocans LPT-CBD, a liposomal drug product designed for chronic pain management, to treat animals like Billy and Dror, two goats with severe skeletal deformities. The treatment has significantly improved their mobility and quality of life without adverse effects. Innocans CEO, Iris Bincovich, and VP of R&D, Eyal Kalo, highlighted the potential of LPT-CBD for transforming pain management in animals and humans. Innocan is an innovator in pharmaceuticals and wellness, focusing on CBD-loaded drug delivery platforms and self-care products.
growth-positive
Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection
Innocan Pharma Corporation has announced its ongoing collaboration with Freedom Farm, a sanctuary for animals with disabilities. The collaboration involves the use of Innocans advanced long-acting injectable LPT-CBD analgesic to alleviate pain in animals like Billy and Dror, two goats with severe skeletal and joint deformities. The treatment has significantly improved their mobility and quality of life without adverse effects. This initiative underscores Innocans commitment to enhancing animal welfare and promoting a compassionate world. The LPT-CBD product is designed for chronic pain management through a prolonged release mechanism of synthetic CBD.
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation announced the positive reception of its LPT-CBD technology at the PAINWeek conference in Las Vegas. The companys poster presentation, delivered by Dr. Joseph V. Pergolizzi, highlighted the potential of long-acting synthetic CBD treatments for pain relief. The presentation attracted significant interest from leading clinicians and potential pharmaceutical partners, emphasizing the innovative approach of LPT-CBD in addressing chronic pain management. The preclinical data presented showed promising results in dogs and minipigs, suggesting prolonged pain relief from a single injection. Innocans CEO, Iris Bincovich, expressed excitement about the recognition received at the conference, underscoring the companys commitment to advancing evidence-based care.
Product StagePartners
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation presented its LPT-CBD technology at the PAINWeek conference in Las Vegas, generating significant interest among participants. The companys innovative approach to pain management using long-acting synthetic CBD was well-received by key opinion leaders and experts in the field. The presentation highlighted the limitations of plant-derived CBD oils and the potential of LPT-CBD to provide prolonged pain relief. Innocans CEO, Iris Bincovich, expressed excitement about the positive response from potential pharmaceutical partners and the opportunity to advance evidence-based care. The companys focus on developing a CBD-loaded liposome drug delivery platform for non-opioid pain management positions it as a pioneer in the pharmaceutical and wellness sectors.
Product StagePartners
growth-positive
Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference
Innocan Pharma Corporation announced the positive reception of its LPT-CBD poster presentation at the PAINWeek conference in Las Vegas. The presentation, delivered by Dr. Joseph V. Pergolizzi, Jr., highlighted the potential of long-acting synthetic CBD treatments for pain relief. The conference, attended by leading clinicians and potential pharmaceutical partners, showcased the promising role of LPT-CBD in advancing pain management. Preclinical data demonstrated the prolonged pharmacokinetics and extended pain relief of LPT-CBD following a single administration to animals. The enthusiastic response from key opinion leaders and experts underscores the potential impact of Innocans innovative approach to addressing unmet needs in chronic pain management.
growth-positive
Innocan Pharma Announces Details of Proposed Share Consolidation
Innocan Pharma Corporation announced a share consolidation as part of its plan to complete a public offering in the United States and list its shares on the NASDAQ Capital Market. The consolidation involves converting 65 pre-consolidation shares into one post-consolidation share. This move is a step towards a proposed public offering of units, each consisting of one common share and one warrant. The company has filed a registration statement with the SEC, and ThinkEquity LLC is acting as the representative underwriter for the offering. The listing on NASDAQ is expected to enhance the companys visibility and access to capital markets.
Public TradingPIPE/PO
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that further to its press...
Innocan Pharma Corporation announced a share consolidation as part of its strategy to complete a public offering in the United States and list its shares on the NASDAQ Capital Market. The consolidation will reduce the number of common shares from 292,420,157 to approximately 4,498,772. This move is aimed at facilitating a proposed public offering of units, each consisting of one common share and one warrant. ThinkEquity LLC is acting as the representative underwriter for the offering. The company has filed a registration statement with the SEC, which is yet to become effective. Innocan is an innovator in pharmaceuticals and wellness, focusing on CBD-loaded drug delivery platforms and self-care products.
Public TradingPIPE/PO
growth-positive
Innocan Pharma Announces First Half Of 2025 Financial Results
Innocan Pharma Corporation announced its financial results for the first half of 2025, showing a significant improvement in operating profitability despite a slight decline in revenue due to market volatility. The company is focused on its strategic vision, delivering opioid-free chronic pain relief solutions and exploring growth opportunities in the Consumer Wellness segment. Innocan is preparing for a U.S. public offering, aiming to list on the Nasdaq Capital Market. The company is advancing its LPT-CBD platform, currently in late pre-clinical development, and is expanding its distribution channels to strengthen its market presence.
Public TradingProduct Stage
growth-positive
Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada
Innocan Pharma Corporation is set to showcase its innovative LPT-CBD product at the PAINWeek conference in 2025. The company will present a poster detailing the pharmacokinetics and efficacy of its long-acting synthetic cannabidiol (CBD) solution for chronic pain. This product, currently in preclinical stages, offers a promising non-opioid alternative for pain management, addressing the global opioid dependency crisis. The LPT-CBD is designed as a pharmaceutical-grade, controlled-release injectable, providing steady plasma CBD levels for up to four weeks. Innocans participation in PAINWeek highlights its commitment to advancing pain management solutions and positions the company as a pioneer in the pharmaceutical and biotechnology industries.
Product Stage
growth-positive
TSX Penny Stocks To Watch In July 2025
InnoCan Pharma Corporation, a pharmaceutical technology company, is focused on developing drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients. Despite being pre-revenue, the company has shown promising potential in the pharmaceutical sector, with a market cap of CA$61.41 million. InnoCan Pharma has a strong cash position, covering both short- and long-term liabilities, and has reduced its losses by 22.9% annually over the past five years. Recent positive research results on their LPT-CBD product for pain management and strategic patent allowances in Latin America position the company favorably within the innovative CBD space.
growth-positive
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
Innocan Pharma Corporation has filed a registration statement on Form F-1 with the U.S. SEC for a proposed public offering of units in the United States. Each unit will consist of one common share and one common share purchase warrant. The company has applied to list its shares and warrants on the Nasdaq Capital Market under the symbols INNP and INNPW. ThinkEquity is acting as the sole book-running manager for the offering. Innocan Pharma is an innovator in pharmaceuticals and wellness, developing a CBD-loaded liposome drug delivery platform and a range of self-care and beauty products.
Public Trading
growth-positive
Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
Innocan Pharma Corporation announced the acceptance of a research article on their liposomal-CBD injection in the journal Precision Nanomedicine. The study shows promising results in terms of prolonged release and safety in minipigs. Additionally, Ron Mayron, Executive Chairman and Director, has resigned effective July 1, 2025, with Iris Bincovich temporarily taking over as Chair. The company granted 23,050,000 Restricted Share Units and 1,950,000 stock options to various stakeholders. Innocan continues to innovate in pharmaceuticals with a focus on CBD drug delivery and wellness products.
Management Changes
growth-positive
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology industries, has announced that its narrative review on long-acting synthetic cannabidiol (CBD) for chronic pain has been accepted for presentation at PAINWEEK 2025. The review highlights the potential of synthetic CBD, administered through extended-release formulations, as a non-opioid analgesic alternative. Innocan is developing LPT-CBD, an injectable liposomal drug product designed for sustained release of synthetic CBD, which has shown promising results in animal studies. The product will be showcased at the PAINWEEK conference, providing an opportunity to engage with healthcare professionals and potential pharmaceutical partners. This development underscores Innocans commitment to advancing non-opioid pain management solutions.
Product StagePartners
growth-positive
InnoCan Pharma Leads 3 Noteworthy TSX Penny Stocks
InnoCan Pharma Corporation, a pharmaceutical technology company, is making strides in the market with its innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients. Despite being currently unprofitable, the company has shown significant progress by reducing its losses over the past five years. In Q1 2025, InnoCan Pharma reported sales of US$7.8 million and reduced its net loss to US$0.582 million from US$1.77 million a year ago. The company has recently secured patent approvals in Mexico and made strategic moves in China, enhancing its intellectual property portfolio and potentially opening new markets for growth. These developments indicate a positive trajectory for the company, despite challenges such as auditor concerns about its ability to continue as a going concern.
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation has announced the publication of a peer-reviewed narrative review in the Cureus journal, highlighting the potential of long-acting synthetic cannabidiol (CBD) for chronic pain management. The review, co-authored by experts from Johns Hopkins University and NYU School of Medicine, suggests that synthetic CBD could serve as a non-opioid analgesic alternative, addressing the urgent need for safer pain treatments. Innocans LPT-CBD platform, designed for sustained CBD release, aligns with FDA guidance for non-opioid analgesic development. The company is advancing regulatory submissions to initiate human clinical trials, marking a significant step towards offering a novel pain management solution.
Product StageFDA approved/pending approval
growth-positive
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
Innocan Pharma Corporation has announced the publication of a peer-reviewed narrative review in the Cureus journal, highlighting the potential of long-acting synthetic cannabidiol (CBD) for chronic pain management. The review, co-authored by experts from Johns Hopkins University and NYU School of Medicine, suggests that synthetic CBD could serve as a non-opioid analgesic alternative, reducing reliance on addictive opioids. Innocans LPT-CBD platform, an injectable liposomal drug product, is designed for sustained release of synthetic CBD, offering prolonged pain relief. The company has initiated regulatory submissions to advance LPT-CBD into human clinical trials, aligning with FDAs emphasis on novel, non-addictive pain therapies.
Product StageFDA approved/pending approval
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has announced a peer-reviewed publication in the Cureus journal discussing the potential of long-acting synthetic cannabidiol (CBD) for chronic pain management. The publication highlights the therapeutic promise of Innocans LPT-CBD platform, which offers a non-opioid alternative for pain relief. The platform is designed for sustained release of synthetic CBD, providing prolonged pain relief and reducing opioid dependency. Innocan is advancing regulatory submissions to initiate human clinical trials, aligning with FDA guidance for non-opioid analgesic development. This development is seen as a significant step towards addressing the opioid crisis by offering safer pain management solutions.
Product StageFDA approved/pending approval
growth-positive
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
Innocan Pharma Corporation reported a successful first quarter of 2025, with a 15% increase in revenue to US$7.8 million and a 19% increase in gross profit. The company raised US$1 million through a private placement with its largest shareholder, Tamar Innovest Ltd. Innocan is advancing its intellectual property strategy by securing patents in Asia for its liposomal CBD injection technology. The company received positive feedback from the FDA for its LPT-CBD platform, which aims to provide a non-opioid alternative for chronic pain management. Additionally, Innocan received a sponsor fee waiver from the FDAs Center for Veterinary Medicine for its LPT-CBD product for dogs.
InvestmentFDA approved/pending approval
growth-positive
TSX Penny Stocks To Watch In May 2025
InnoCan Pharma Corporation, a pharmaceutical technology company, is making strides in the development of drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients. Despite being pre-revenue, the company has shown significant progress by reducing losses by 15.1% annually over the past five years. InnoCan Pharma is debt-free and maintains a stable cash runway exceeding three years, which provides financial resilience. Recent strategic moves include securing patent allowances for its CBD-based technologies in Mexico and filing applications in China, enhancing its intellectual property portfolio. These developments are expected to support InnoCans efforts to penetrate new regions and strengthen its position in cannabidiol-based therapeutic solutions.
Product StageInvestment
growth-positive
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
Innocan Pharma Corporation has received a notice of allowance for its patent application in Mexico, covering its proprietary cannabis-based pain relief topical. This patent approval is a significant milestone for Innocan, as it enhances its intellectual property portfolio and positions the company for strategic entry into the Latin American market. The patented formulation combines cannabidiol with minerals to provide fast-acting pain relief, with clinical studies showing effectiveness within 20 minutes. Innocan aims to expand its patent portfolio globally, reinforcing its leadership in cannabidiol-based wellness innovation. The company is also involved in developing a CBD-loaded liposome drug delivery platform for non-opioid pain management.
Product StageExpand
growth-positive
Innocan Pharma Announces Closing of Private Placement
Innocan Pharma Corporation has successfully closed a non-brokered private placement offering, raising $214,839 through the issuance of 1,193,551 units at $0.18 per unit. Each unit includes one common share and one warrant, allowing the purchase of an additional share at $0.25 within four years. The funds will be used for working capital and general corporate purposes. Innocan operates in two segments: Pharmaceuticals, focusing on drug delivery technologies using cannabinoids, and Consumer Wellness, offering self-care products. The pharmaceutical segments LPT CBD-loaded liposome platform is in preclinical trials for epilepsy and pain management. The company emphasizes its commitment to innovation and improving patient quality of life.
Investment
growth-positive
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
Innocan Pharma Corporation is expanding its intellectual property protection in the Chinese pharmaceutical market by filing a divisional application for its liposome-based CBD technology patent. This move follows a recently granted patent in India and is part of Innocans strategy to strengthen its global IP portfolio. The companys synthetic CBD-loaded Liposome Injection Platform (LPT-CBD) is developed in collaboration with experts from the Hebrew University in Jerusalem. Innocan also announced its intention to complete a non-brokered private placement to raise CAD $150,000, expected to close by April 14, 2025. This strategic expansion and investment aim to support Innocans broader business objectives in the rapidly growing Asian pharmaceutical market.
Product StageInvestment
growth-positive
Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million
Innocan Pharma Corporation reported a significant increase in its financial performance for the year ending December 31, 2024. The companys revenue rose by 114.6% to US$29.4 million, largely driven by the strong sales performance of its subsidiary, BI Sky Global Ltd. Gross profit also saw a substantial increase, and operating losses decreased by 67%. The company is focused on advancing its drug delivery platform technologies, particularly in non-opioid chronic pain management solutions. Innocans CEO expressed excitement over the companys achievements and commitment to innovation and strategic execution. BI Sky Global is leveraging data and analytics to enhance its position in the beauty and personal care industry.
growth-positive
InnoCan Pharma And 2 Other TSX Penny Stocks With Growth Potential
InnoCan Pharma Corporation, a pharmaceutical technology company, is focusing on developing drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients. The company operates internationally with a market cap of CA$60.92 million. Despite being unprofitable, InnoCan Pharma is debt-free and has secured a patent in India for its liposome-based cannabinoid technology. The company recently raised US$1 million through private placements to support its development efforts. The management team has received positive FDA feedback for their LPT-CBD platform, although the stock remains volatile. The company is positioned for growth, leveraging its strong financial health and strategic advancements.
Investment
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously...
growth-positive
Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited
Innocan Pharma Corporation has successfully closed a non-brokered private placement offering with its largest shareholder, Tamar Innovest Ltd., raising US $1,000,000. The offering includes a secured convertible debenture and common share purchase warrants. The debenture, maturing in two years, bears a 10% annual interest and is convertible into common shares. The funds will be used for working capital and general corporate purposes. Tamar Innovest, managed by Ralph Bossino, is a significant shareholder and insider of Innocan, making this a related party transaction under MI 61-101. The transaction was approved by independent directors.
Investment
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its...
growth-positive
Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest
Innocan Pharma Corporation announced an offering of a debenture unit to its largest shareholder, Tamar Innovest Ltd., for gross proceeds of US $1,000,000. The debenture unit includes a secured convertible debenture and common share purchase warrants. The debenture matures in two years, bearing an interest rate of 10% per annum, and is convertible into common shares. The offering is expected to close around March 6, 2025, with proceeds intended for working capital and general corporate purposes. Tamar Innovests participation is considered a related party transaction under MI 61-101, but exemptions apply as the offerings fair market value is less than 25% of Innocans market capitalization.
Investment
growth-positive
TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities
InnoCan Pharma Corporation, a pharmaceutical technology company, is gaining attention due to its innovative drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients. Despite being pre-revenue and unprofitable, the company has made progress by reducing losses over the past five years. It recently received a patent in India and positive feedback from the FDA for its LPT-CBD platform aimed at chronic pain management. InnoCan is debt-free and has a cash runway for 1.5 years, bolstered by recent private placements totaling CAD 635,444.60. The company operates internationally, with a market cap of CA$66.73 million.
Investment
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation has been granted a patent in India for its prolonged-release pharmaceutical formulation using liposomes to encapsulate cannabinoids. This patent covers Innocans synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of synthetic CBD into the bloodstream. The patent strengthens Innocans global intellectual property portfolio and supports the development of LPT-CBD as a non-opioid alternative for chronic pain management. Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the platform maximizes the bioavailability and therapeutic effects of cannabinoids. Innocan is advancing the LPT-CBD platform under its intellectual property portfolio, with positive feedback from the U.S. FDA following a successful pre-IND meeting.
Product StagePartners
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation has been granted a patent in India for its prolonged-release pharmaceutical formulation using liposomes to encapsulate cannabinoids. This patent protects Innocans synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), which is designed for precise dosing and sustained release of synthetic CBD into the bloodstream. The patent strengthens Innocans global patent applications and enhances the proprietary value of its novel liposome-based cannabinoid technology. Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the platform maximizes the bioavailability and therapeutic effects of cannabinoids. The company is advancing LPT-CBD as a non-opioid alternative for chronic pain management, with positive feedback from the FDA following a successful pre-IND meeting.
Product Stage
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation has announced the successful use of its Liposomal CBD injection (LPT-CBD) in treating osteoarthritis in a donkey, demonstrating its potential for both human and veterinary applications. The treatment provided quick and sustained pain relief, significantly improving the mobility of the donkey. This success adds to the evidence supporting LPT-CBDs effectiveness in large animals and its potential as a non-opioid alternative for chronic pain management in humans. Innocan has completed a pre-IND meeting with the FDA, indicating progress towards human trials. The company is a pioneer in the pharmaceutical and biotechnology industries, focusing on innovative drug delivery platforms and wellness products.
Product Stage
growth-positive
Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis
Innocan Pharma Corporation has announced the successful use of its liposomal CBD injection (LPT-CBD) in treating an elderly donkey suffering from osteoarthritis. The treatment provided quick and sustained pain relief, significantly improving the donkeys mobility. This success demonstrates the potential of LPT-CBD for both veterinary and human applications. The company has completed a successful pre-IND meeting with the FDA, indicating the potential for LPT-CBD as a non-opioid alternative for chronic pain management in humans. The positive results in animals suggest a promising future for this innovative treatment in both veterinary and human medicine.
Product Stage
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation, through its subsidiary BI Sky Global, has successfully completed the Human Repeated Insult Patch Test (HRIPT) for its cosmetic products, ensuring their safety. The company has also achieved a significant sales milestone, averaging 5,000 units sold per day in 2024, which is a substantial increase compared to typical production quantities. This achievement highlights the companys strong market demand and positions it for further expansion in sales and marketing. Innocan is an innovator in the pharmaceuticals and wellness sectors, developing a CBD-loaded liposome drug delivery platform and a wide range of self-care and beauty products. The company is focused on advanced online sales through its subsidiary.
Product StageCustomers
growth-positive
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone
Innocan Pharma Corporation, through its subsidiary BI Sky Global, has successfully completed the Human Repeated Insult Patch Test (HRIPT) for its cosmetic products, ensuring their safety. The company has also achieved a significant sales milestone, averaging 5,000 units sold per day in 2024, which is a substantial increase compared to typical production quantities. This achievement highlights the strong demand for Innocans products and positions the company for further expansion in sales and marketing. Innocan is an innovator in pharmaceuticals and wellness, with a focus on CBD-loaded drug delivery platforms and high-performance self-care products.
Customers
growth-positive
TSX Penny Stock Picks For January 2025
InnoCan Pharma Corporation, a pharmaceutical technology company, is focusing on innovative CBD drug delivery platforms. Despite being unprofitable, the company has reduced its losses by 10.5% annually over five years and remains debt-free. It has a cash runway for 1.5 years if current free cash flow trends persist. Recent private placements raised CAD 635,444.60 to support operations, and promising safety results from its LPT-CBD product in minipigs suggest potential in chronic pain treatment markets. The company is navigating the penny stock landscape with a market cap of CA$49.32 million.
Investment
growth-positive
FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025
Innocan Pharma Corporation announced that the FDAs Center for Veterinary Medicine has granted the company a sponsor fee waiver for its LPT-CBD product for the second consecutive year. This waiver, under the Animal Drug User Fee Act, recognizes Innocans innovative approach to developing animal drug products. The LPT-CBD product is designed for subcutaneous injection to manage chronic pain in dogs, offering precise and sustained CBD release. This development is significant given the growing interest in CBD products among pet owners. Innocans CEO and R&D Director highlighted the importance of this milestone in advancing their products development and providing effective pain management solutions for pets.
Product Stage
growth-positive
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60
Innocan Pharma Corporation announced the successful closing of a non-brokered private placement offering, raising gross proceeds of $635,444.60. The offering involved the issuance of 3,177,223 units at C$0.20 per unit, each comprising one common share and one common share purchase warrant. The warrants allow holders to purchase additional shares at C$0.28 within four years. The funds will be used for working capital and general corporate purposes, supporting Innocans strategic direction and proprietary CBD-loaded liposome platform technology. CEO Iris Bincovich expressed satisfaction with the investor confidence reflected in the successful funding round. The securities are not registered under U.S. securities laws and cannot be offered or sold in the U.S. without registration or exemption.
Investment
/CNW/ -- Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced...
/PRNewswire/ -- Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously...
growth-positive
InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks
InnoCan Pharma Corporation, a pharmaceutical technology company, is making strides in the market despite recent volatility in the Canadian market. The company, which focuses on drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients, has shown promising developments. With a market cap of CA$60.26 million, InnoCan Pharma has significantly reduced its net losses and increased sales to US$24.04 million for the first nine months of 2024. The company remains debt-free, which enhances its financial stability. A recent private placement aims to raise CAD 700,000 to support further research and development. Positive results from safety assessments and compassionate therapy studies suggest potential future applications for its liposomal-CBD products.
Investment
growth-positive
Innocan Pharma Announces Private Placement of Units
Innocan Pharma Corporation announced its intention to complete a non-brokered private placement of up to 3,500,000 units at C$0.20 per unit, aiming to raise up to C$700,000, with an additional 15% over-allotment option. The offering is expected to close around December 31, 2024. Each unit will include one common share and one common share purchase warrant, allowing the purchase of an additional share at C$0.28 within four years. The proceeds will be used for working capital and general corporate purposes. Innocan specializes in pharmaceuticals and wellness, focusing on CBD-loaded liposome drug delivery and self-care products. The securities will be subject to Canadian securities laws and are not registered for sale in the United States.
Investment
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a...
Innocan Pharma Corporation has announced a non-brokered private placement offering of up to 3,500,000 units at C$0.20 per unit, aiming to raise gross proceeds of up to C$700,000, with an additional 15% over-allotment option. The offering is expected to close around December 31, 2024. Each unit will include one common share and one common share purchase warrant, allowing the purchase of an additional share at C$0.28 within four years. The funds will be used for working capital and general corporate purposes. Innocan operates in the pharmaceuticals and wellness sectors, focusing on CBD-loaded liposome drug delivery and self-care products. The announcement is forward-looking and subject to various risks and uncertainties.
Investment
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete...
Innocan Pharma Corporation has announced a non-brokered private placement offering of up to 3,500,000 units at a price of C$0.20 per unit, aiming to raise up to C$700,000, with an additional 15% over-allotment option. The offering is expected to close by December 31, 2024. Each unit comprises one common share and one common share purchase warrant, allowing the purchase of an additional share at C$0.28 within four years. The funds will be used for working capital and general corporate purposes. Innocan operates in the pharmaceuticals and wellness sectors, focusing on CBD-loaded drug delivery platforms and self-care products. The announcement includes forward-looking statements subject to various risks and uncertainties.
Investment
growth-positive
Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024
Innocan Pharma Corporation announced significant advancements in its research and development efforts for 2024, focusing on its liposome-cannabidiol technology (LPT-CBD). The company achieved high CBD bioavailability and long-lasting pain relief in preclinical studies. Innocan secured agreement from the FDA on its preclinical and Phase 1 clinical development plan for LPT-CBD as a treatment for chronic pain in humans. The FDA also recognized LPT-CBDs development under the 505(b)(2) regulatory pathway, providing an accelerated route to commercialization. Additionally, the FDAs Center for Veterinary Medicine granted Innocan a fee waiver for 2024 and issued an Investigational New Animal Drug number, facilitating the development of LPT-CBD as a veterinary drug. These achievements position Innocan to accelerate its development in 2025.
growth-positive
3 TSX Penny Stocks With Market Caps Over CA$20M To Watch
InnoCan Pharma Corporation, a pharmaceutical technology company, is experiencing significant revenue growth, with third-quarter sales reaching US$8.62 million, doubling from the previous year. Despite being unprofitable, the company has reduced its net loss and maintains a robust cash position. The management team is experienced, aiding in strategic decisions like the FDAs positive response to their LPT-CBD product pathway, potentially expediting market entry. However, shareholder dilution occurred last year with a 7.1% increase in shares outstanding. The company operates internationally, with a market cap of CA$65.99 million. The article highlights the potential growth opportunities in penny stocks within the Canadian market, supported by a resilient consumer base and rising corporate profits.
growth-positive
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs
Innocan Pharma Corporation has reported positive results from a basic safety assessment study of its LPT-CBD drug, administered as a single injection in Göttingen minipigs. The study, which involved three ascending doses over a 28-day period, showed no adverse events, with all animals exhibiting normal weight gain and excellent tolerance to the drug. This promising safety profile supports the feasibility of LPT-CBDs safety evaluation and paves the way for upcoming regulatory milestones. LPT-CBD is an innovative injectable liposomal formulation designed for sustained release of CBD, targeting chronic pain treatment. Innocan operates in pharmaceuticals and consumer wellness, focusing on drug delivery technologies and self-care products.
growth-positive
Innocan Pharma Reports Third Quarter 2024 Financial Results
Innocan Pharma Corporation reported significant financial growth for the nine-month period ending September 30, 2024. The company achieved a 174% year-over-year increase in revenue, reaching US $24 million, driven by strong sales from its subsidiary, BI Sky Global Ltd. Gross profit for the same period rose by 183% to US $21.8 million. The company also turned an operating profit of US $0.4 million, a substantial improvement from the previous years loss. Innocans CEO, Iris Bincovich, highlighted the companys focus on pharmaceutical innovation, particularly in chronic pain management, as a key driver of this success. The companys online platform and new product introductions contributed to the impressive financial results.
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on...
Innocan Pharma Corporation reported significant financial growth for the three and nine-month periods ending September 30, 2024. The company achieved a 174% year-over-year increase in nine-month revenues, reaching US $24 million, and a 111% increase in three-month revenues, amounting to US $8.6 million. Gross profit for the nine-month period rose by 183% to US $21.8 million, while net profit increased by US $2.1 million compared to the previous year. The growth is attributed to strong sales from its subsidiary, BI Sky Global Ltd., and the successful introduction of new products. Innocan focuses on innovative drug delivery platforms, particularly for non-opioid chronic pain management, and continues to expand its wellness product portfolio.
growth-positive
Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand
Innocan Pharma Corporation has strategically decided to focus on its Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in animals and humans, following positive progress with the FDA. The FDA has supported Innocans LPT-CBD platform for human use under the 505(b)(2) pathway, expediting commercial approval. Additionally, the FDAs Center for Veterinary Medicine has issued an Investigational New Animal Drug designation. With significant market potential in the U.S. pet industry, Innocan aims to capitalize on the growing demand for effective veterinary health products. Consequently, Innocan is terminating its Cannabinoid-Loaded Exosome project with Ramot of Tel Aviv University to concentrate resources on LPT-CBD.
Partners
growth-positive
InnoCan Pharma Leads 3 Promising Penny Stocks On TSX
InnoCan Pharma Corporation, a pharmaceutical technology company, is highlighted for its promising developments in liposomal-CBD technology for pain relief in animals. Despite being unprofitable, the company has shown improved earnings and reduced losses over five years, with US$8.64 million in sales reported for Q2 2024. The company is debt-free, with short-term assets exceeding liabilities, and has a seasoned management team. Recently, shareholder dilution occurred due to private placements aimed at raising capital for future growth initiatives. The article positions InnoCan Pharma as a promising investment opportunity within the penny stocks category, given its strong financial health and growth potential.
Investment
growth-positive
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma, a leader in chronic pain management through Liposomal CBD drug products, announced its participation in The ThinkEquity Conference on October 30, 2024, in New York. The company will discuss its recent regulatory achievements, including securing FDA approval for a 505(2)(b) abbreviated pathway for human health applications and an INAD number for animal health applications. CEO Iris Bincovich will present at the conference, and the management team will hold one-on-one meetings with investors. Innocans participation in the conference and its regulatory milestones are expected to positively impact the companys growth and investment opportunities.
Investment
growth-positive
Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience
Innocan Pharma Corporation, a leader in chronic pain management through Liposomal CBD drug products, announced its participation in the 2024 ThinkEquity Investor Conference on October 30 in New York. The company will highlight its recent regulatory achievements, including securing FDA approval for a 505(2)(b) abbreviated pathway for human health applications and an Investigational New Animal Drug number for animal health applications. Innocans CEO, Iris Bincovich, will present at the conference, which features over 75 companies and offers networking opportunities with investors and industry executives. Additionally, Innocan has relaunched its website to improve communication with collaborators and investors. The companys innovative CBD-loaded liposome drug delivery platform aims to provide non-opioid pain management solutions.
growth-positive
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
Innocan Pharma Corporation has announced promising results from a multi-year compassionate therapy using liposomal-CBD (LPT-CBD) injections for pain relief in dogs with osteoarthritis. The therapy has shown consistent pain reduction and improved mobility, with effects lasting several weeks. This positions LPT-CBD as a potential breakthrough solution for managing chronic pain in animals and possibly humans. The company is committed to advancing FDA approval for this treatment. Innocan Pharma is an innovator in pharmaceuticals and wellness, developing a CBD-loaded liposome drug delivery platform for non-opioid pain management. The company also markets a wide range of self-care and beauty products. The announcement highlights the potential of LPT-CBD as a monthly treatment for chronic pain conditions, providing sustained relief.
growth-positive
Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide
Innocan Pharma Corporation announced that Dr. Joseph V. Pergolizzi, Jr., a member of its Scientific Advisory Board, has been recognized among the top 2% most-cited scientists globally by Stanford University. This accolade highlights Dr. Pergolizzis significant contributions to medical science and his role in advancing Innocans pharmaceutical research and development efforts. His expertise is crucial in promoting pharmaceutical human product R&D and supporting the companys planned FDA filings for new medications. Innocan Pharma focuses on developing innovative drug delivery technologies using cannabinoids to improve patients quality of life. The recognition of Dr. Pergolizzi is seen as a positive development for Innocan, enhancing its reputation and credibility in the pharmaceutical industry.
growth-positive
Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting
Innocan Pharma Corporation announced a positive response from the FDA following a successful pre-IND Type B meeting for its lead drug product, Liposomal Technology-CBD (LPT-CBD). The FDA agreed to the submission of LPT-CBD under the 505(b)(2) New Drug Application, which could expedite its approval process. Innocan has also aligned with the FDA on the non-clinical development plan and clinical study design for a Phase I clinical study. This milestone is significant for Innocan as it advances its innovative approach to chronic pain management, potentially benefiting millions of sufferers. The company operates in both the pharmaceutical and consumer wellness segments.
Customers
growth-positive
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology...
Innocan Pharma Corporation announced a positive response from the FDA following a successful pre-IND Type B meeting for its lead drug product, Liposomal Technology-CBD (LPT-CBD). The FDA has agreed to the submission of LPT-CBD under the 505(b)(2) New Drug Application, which typically allows for a faster route to patent utilization and commercial approval. This milestone enables Innocan to advance its patent-protected innovation and proceed with its clinical study for chronic pain management. The company has aligned with the FDA on its non-clinical development plan and clinical study design for the proposed Phase I clinical study. This development is expected to significantly enhance the ability of clinicians to address existing gaps in chronic pain treatment.
Customers
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation announced a positive response from the FDA following a successful pre-IND Type B meeting for its lead drug product, Liposomal Technology-CBD (LPT-CBD). The FDA has agreed to the submission of LPT-CBD under the 505(b)(2) New Drug Application pathway, which could expedite its approval process. Innocan has also aligned with the FDA on its non-clinical development plan and clinical study design for a Phase I clinical study. This milestone is crucial for advancing LPT-CBD to market, potentially providing new opportunities for chronic pain management. The company is committed to addressing the significant unmet needs in chronic pain treatment.
Customers
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
growth-positive
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and...
Innocan Pharma Corporation announced the completion of a non-brokered private placement offering, raising C$1,105,659.50 through the sale of 5,025,725 units at C$0.22 per unit. Each unit includes one common share and one common share purchase warrant, with the warrants exercisable at C$0.32 for four years. The funds will be used for working capital and general corporate purposes. Additionally, the company granted 300,000 stock options to consultants, with vesting schedules extending to August 2025. Innocan Pharma operates in pharmaceuticals and consumer wellness, focusing on innovative drug delivery technologies and self-care products.
Investment
growth-positive
Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration
Innocan Pharma Corporation has announced that its subsidiary, BI Sky Global, has successfully registered all its products under the FDAs Modernization of Cosmetics Regulation Act of 2022. The company also announced its intention to complete a non-brokered private placement of up to 4,000,000 units of the Company at a price of C$0.22 per Unit for gross proceeds up to C$880,000. The offering is expected to close on or around August 29, 2024. The proceeds will be used for working capital and general corporate purposes.
Investment
growth-positive
Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over 2.8X to $8.6 Million
Innocan Pharma Corporation has reported its financial results for the first half of 2024, showing a revenue growth of over 3.3X to $15.4 million. The companys revenues increased by 177% to $8.6 million in Q2 2024, primarily due to strong sales growth from its subsidiary, BI Sky Global Ltd. The companys gross profit also increased by 201% to $8.0 million in Q2 2024. The CEO of Innocan, Iris Bincovich, expressed excitement about the potential of their LPT technology, which enables the prolonged release of CBD to manage chronic pain.
CustomersExpand
growth-positive
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
Innocan Pharma Corporation has received a sponsor fee waiver and an Investigational New Animal Drug (INAD) number from the FDAs Center for Veterinary Medicine (CVM) for its LPT-CBD product. The INAD designation will facilitate correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The companys LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. The fee waiver granted by CVM supports Innocans development and pursuit of innovative animal drug products and technology.
CustomersPartners
growth-positive
Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
Innocan Pharma Corporation has engaged Dr. William K. Schmidt, Past-President of the Eastern Pain Association, to support its LPT-CBD submission process to the FDA for chronic pain. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. His expertise will contribute to Innocans LPT-CBD submission process with the FDA. Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. It focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients quality of life.
Partners
growth-positive
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Innocan Pharma Corporation has successfully concluded a preliminary safety evaluation of its single injection and sustained-release LPT-CBD on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events. The company also announced the grant of 290,000 restricted share units to consultants, and 2,380,000 stock options to employees and consultants. The company is focused on developing innovative drug delivery platform technologies with cannabinoids science, to treat various conditions to improve patients quality of life.
Investment
growth-positive
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
Innocan Pharma Corporation has announced its Q1 2024 financial results, showing a 334% YoY increase in revenues to $6.8 million, primarily due to strong sales growth from its subsidiary, BI Sky Global Ltd. Gross profit also increased 338% YoY to $6 million. The companys LPT-CBD technology for chronic pain management has made significant advancements, with a meeting with the FDA scheduled for July. The online platform of BI Sky Global has performed well, achieving more than half of the revenues recorded in 2023 in just one quarter. The company anticipates continued growth by introducing new product categories and innovative formulations.
CustomersExpand
growth-positive
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain
Innocan Pharma Corporation has announced significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, a non-opioid pain management solution. The U.S. Food and Drug Administration (FDA) has granted Innocan an Investigational New Drug (IND) number and approved an initial meeting with the company to discuss the strategic path forward. The meeting, set for July 31, 2024, will be key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain.
InvestmentExpand
growth-positive
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Innocan Pharma Corporation, a pharmaceutical and biotechnology company, has successfully used a liposomal-CBD injection to treat a female donkey suffering from laminitis, an inflammatory disease that causes extreme pain and limited mobility. The treatment provided immediate pain relief and improved mobility, eliminating the need for euthanasia. Innocans CEO, Iris Bincovich, sees the treatment as strong evidence of liposomal-CBDs potential to improve the lives of animal and potentially human patients. The company is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.
Customers
growth-positive
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation has initiated the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its Liposome-Cannabidiol (LPT-CBD) injectable treatment for chronic pain. The company has submitted a Pre-IND Meeting Request Letter, marking the first phase in the FDA approval process. The global market for pain therapeutics is expected to exceed US$100 billion by 2032, and Innocans therapy, which requires only one single monthly subcutaneous injection, is positioned as an alternative to opioid-based approaches.
InvestmentExpand
growth-positive
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation, a pharmaceutical technology company, has announced its audited financial consolidated results for the year ended December 31, 2023. The company saw a 534% increase in revenues to US$13.7 million, primarily due to the robust sales performance of its subsidiary, BI Sky Global Ltd. Gross profit increased 568% year-over-year to US$12.0 million. The company also completed a $1.5 million capital raise in March 2024. Innocan is pursuing FDA approval of its LPT CBD-loaded liposome platform for use by patients who suffer from Chronic pain.
CustomersInvestment
growth-positive
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Innocan Pharma Corporation has signed an agreement with the Hebrew University to initiate the FDA approval process for its liposome CBD platform (LPT-CBD). The company is now focusing on the essential development steps to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases. This includes defining the physical and chemical specifications of LPT-CBD and expanding its production from small laboratory quantities to large pharmaceutical-grade quantities.
PartnersExpand
growth-positive
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
Innocan Pharma Corporation has announced the successful closure of its non-brokered private placement offering, raising $1,988,210. The company issued 7,952,840 units at $0.25 per unit. Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the holder to purchase one common share at $0.32 for a period of four years from the date of issuance. The funds raised will be used for working capital and general corporate purposes.
Investment
growth-positive
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study
Innocan Pharma Corporation has announced its intention to complete a private placement of up to 12,000,000 units of the company at a price of C$0.25 per unit, potentially raising up to C$3,000,000. The company also revealed the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), which indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. The study showed that CBD was found in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them.
Investment
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
growth-positive
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024
Innocan Pharma Corporations CEO, Iris Bincovich, will be a speaker at the White Label World Expo in London on February 27th and 28th. She will be discussing the science behind CBD products. The White Label World Expo is a major event for the white label industry, providing a platform for sellers, suppliers, and buyers to network and explore opportunities. Innocans participation at the expo supports the companys diversified market access strategy, which includes joint ventures, online marketplaces, brick-and-mortar distribution, and white label partnerships.
Partners
growth-positive
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Innocan Pharma Corporation, a pharmaceutical tech company, is making strides in the pharmaceutical technology industry with its dual focus on pharmaceuticals and consumer wellness. The companys product development is centered around its proprietary CBD-loaded liposome platform technology (LPT), designed for both human and animal applications. Innocans entry into the global pain management market, which is expected to reach $109 billion by 2032, positions it well for growth. The companys product portfolio includes advanced CBD-based formulations for both injectable and topical applications. Innocan is currently pursuing FDA approval for its human pharmaceutical applications and expects to submit pre-investigational new drug applications by the end of March, 2024.
CustomersInvestmentExpand
growth-positive
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST
Innocan Pharma Corporation will provide a corporate update to the investment community and its shareholders through a Zoom livestream on February 12, 2024. The update will include a presentation by Innocans CEO Iris Bincovich describing the key research milestones achieved by the Company to date. Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. The company is developing innovative drug delivery platform technologies with cannabinoids science, to treat various conditions to improve patients quality of life.
Management Changes
growth-positive
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration
Innocan Pharma Corporation is preparing to submit an application to the United States Food and Drug Administration (FDA) for the human application of its LPT CBD platform. The company has established a specialized team of drug development and approval experts to guide them through the process. The team includes Dr. Robert B. Raffa, Dr. Kory J. Engelke, and Dr. Joseph V. Pergolizzi Jr., all of whom have extensive experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.
Management ChangesExpand
growth-positive
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022
Innocan Pharma Corporation has announced its financial results for Q3 2023, showing significant growth. The companys revenue for the period was $4.083 million, a 445% increase from $749,000 in Q3 2022. Gross profit also increased by approximately 412% to $3.664 million, up from $715,000 in the same period the previous year. The company attributes this growth to the robust sales performance of its subsidiary, B.I. Sky Global Ltd, and its strategic focus on FDA approvals for its LPT-CBD-loaded liposome platform.
Customers
growth-positive
Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals
Innocan Pharma Corporation has announced positive findings from its research into LPT-CBD, a drug designed for the treatment of chronic diseases. The drug was found to be well-tolerated in animals over a six-month period, with no adverse effects and noticeable pain relief. The companys research team, led by Prof. Chezy Barenholz, believes that LPT-CBD can be used safely for long-term therapy. The company is now closer to its goal of FDA approval for LPT-CBD. Innocan Pharma operates in two segments: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals division is developing drug delivery platforms infused with cannabinoid science, while the Consumer Wellness division focuses on self-care products.
InvestmentExpand
growth-positive
Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research
Innocan Pharma Corporation has announced significant findings in its research on animals that metabolize cannabidiol (CBD) in a similar way to humans. The company believes this discovery could strengthen its application to the FDA for new drug approval. The liposomal CBD injection administered to various animal species resulted in pain relief for several weeks, indicating potential for revolutionizing healthcare for animals and humans. Innocan is a pharmaceutical tech company that operates in Pharmaceuticals and Consumer Wellness, focusing on developing innovative drug delivery platform technologies with cannabinoids science.
InvestmentExpand
Growth-Positive
Innocan Pharma Announces Closing of Second and Final Tranche of Financing
Innocan Pharma Corporation has announced the closure of the second and final tranche of its private placement offering, raising aggregate gross proceeds of $1,627,682.40. The offering was led by Research Capital Corporation. The funds raised will be used to fund the companys pre-investigational new drug meeting with the FDA, the investigational new animal drug meeting with the FDA, and for the expansion of the companys derma-cosmetic product distribution. Innocan operates under two main segments: Pharmaceuticals and Consumer Wellness, focusing on developing innovative drug delivery platform technologies.
InvestmentExpand
Growth-Positive
Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update
Innocan Pharma Corporation has announced the closure of the first of two tranches of its private placement offering, raising $426,060. The offering was led by Research Capital Corporation. The funds raised will be used to fund the companys pre-investigational new drug meeting with the FDA, the investigational new animal drug meeting with the FDA, and for the expansion of the companys derma-cosmetic product distribution. The company expects to complete a second and final tranche of the offering in the following week.
InvestmentExpand
growth-positive
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
Innocan Pharma Corporation has announced a private placement offering of units of the company, with Research Capital Corporation as the sole agent and bookrunner. The offering is expected to raise up to $3,000,000, with each unit priced at $0.30. The net proceeds from the offering will be used to fund the companys pre-investigational new drug meeting with the FDA, the investigational new animal drug meeting with the FDA, and for the expansion of the companys derma-cosmetic product distribution. The offering is expected to close in the week of October 10, 2023.
InvestmentExpand
growth-positive
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board
Innocan Pharma Corporation has announced the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi is a distinguished expert in the field of pain management and critical care medicine and will be instrumental in the companys upcoming planned FDA filing for human medications. The global market for pain management is expected to grow significantly, providing a promising landscape for Innocans planned FDA upcoming FDA. The Company expects that Dr. Pergolizzis expertise will contribute to the success of this venture.
Management Changes
growth-positive
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test
Innocan Pharma Corporation, a pharmaceutical technology company, announced successful results from a controlled efficacy test of its hair care cream. The trial revealed significant hair growth improvements in male and female participants over a 14-day period. 91% of participants reported stronger hair and 100% reported reduced hair loss. The product, enriched with cannabinoids, peptides, and other natural ingredients, resulted in increased hair density and thickness. The trial supports Innocans commitment to diversifying and enhancing its range of wellness solutions.
CustomersExpand
growth-positive
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection
Innocan Pharma Corporation has announced the results of a clinical study on the pain-relieving effects and safety of its subcutaneous liposomal CBD for dogs with osteoarthritis. The study showed that CBD plasma levels were detected for six weeks following a single dose of Liposomal-CBD, effectively decreasing pain and improving well-being in affected dogs. The study highlights the potential of Innocans innovative formulations and drug delivery systems. Innocan Pharma has a research and license agreement with The Hebrew University of Jerusalem for the development of CBD-loaded liposomes. The company is focused on the development of drug delivery platforms containing CBD for various applications, including pain relief and the treatment of central nervous system disorders.
Customers
growth-positive
Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022
Innocan Pharma Corporation has announced its financial results for Q2 2023, reporting a significant increase in revenue and gross profit compared to the same period in 2022. The company achieved revenues of US$3.121 million, representing a growth of 652%, and a gross profit of US$2.656 million, an increase of approximately 1,141%. The strong performance was attributed to the robust sales from Innocans subsidiary, B.I. Sky Global Ltd. The company remains focused on integrating cannabinoids with existing drugs and is optimistic about the future. Innocan operates in the Pharmaceuticals and Consumer Wellness segments, developing drug delivery platform technologies and self-care products. For more information, visit the companys profile at www.sedar.com.
CustomersInvestment
growth-positive
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment
Innocan Pharma Corporation has unveiled the successful results of a controlled efficacy trial for their diabetic foot relief cream. The trial demonstrated that the cream, which contains cannabinoids and other natural ingredients, is highly effective in alleviating foot dryness and reducing the risk of skin cracking in individuals with diabetes. The trial involved a diverse group of volunteers with diabetes and showed significant improvements in foot hydration and a decrease in epidermal water loss. Additionally, 97% of the trial participants reported immediate improvement in foot skin dryness and increased hydration. The global market for diabetic foot ulcer treatment is projected to reach approximately USD 14.8 billion by 2030. Innocan Pharma Corporation aims to provide safe and effective solutions for diabetic patients and improve their quality of life.
Customers
growth-positive
Innocan Pharma Announces Closing of Private Placement
Innocan Pharma Corporation has closed a non-brokered private placement offering of 8,409,735 units at a price of C$0.23 per unit, raising aggregate gross proceeds of C$1,934,239. The proceeds will be used for working capital and general corporate purposes. Each unit consists of one common share, one-half of one Class A common share purchase warrant, and one-half of one Class B common share purchase warrant. The securities issued will be subject to a four-month hold period, in accordance with applicable Canadian securities laws.
Investment
Innocan Pharma Announces Private Placement of Units at a 9% Prime Above Share Price
growth-positive
Innocan Pharma Unveils Groundbreaking Veterinary Breakthroughs at EAVPT 2023 Congress
Innocan Pharma Corporation announces its participation in the 15th International Congress organized by the Executive Committee of the European Association of Veterinary Pharmacology and Toxicology. The company will present two groundbreaking studies on the therapeutic efficacy of liposomal cannabidiol (CBD) injection for dogs with osteoarthritis. Innocan Pharma aims to revolutionize animal health and provide new avenues for effective treatments. The event will serve as a platform for collaboration and innovation in the field of veterinary pharmacology and toxicology. Innocan Pharma operates in the Pharmaceuticals and Consumer Wellness segments, focusing on drug delivery technologies and self-care products.
Partners
growth-positive
InnoCan Pharma Submits New Patent Applications for Advanced Pain Relief Technology
InnoCan Pharma has filed a patent application for its combined Magnesium and Cannabis topical pain-relief technology. The application reflects the broad spectrum of cannabinoids and variable dosage, highlighting the potential of this novel technology. The company aims to expand its cannabis-based intellectual property portfolio and continue filing additional patent applications. InnoCan Pharma is focused on developing innovative drug delivery platform technologies using cannabinoids to treat various conditions. It also develops and markets self-care products in the consumer wellness segment. The company is positioning itself at the forefront of novel cannabis-based therapeutic solutions.
Expand
growth-positive
Innocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues Compared to Q1 2022
Innocan Pharma Corporation has reported its financial results for the first quarter of 2023, showing growth in revenue and gross profit compared to the same period last year. The company generated approximately $1.6 million in revenue, representing a $1.3 million increase. Gross profit for the quarter was approximately $1.4 million, compared to $78,000 in the previous year. The companys cash balance stood at approximately $4.1 million, a 17% decrease from the prior year due to strategic investments. Innocan operates in the pharmaceuticals and consumer wellness segments, focusing on drug delivery platform technologies and self-care products. The company has a joint venture called BI Sky Global Ltd. that focuses on developing advanced targeted online sales.
InvestmentCustomers
growth-positive
Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat
Innocan Pharma successfully treated a 4-year-old goat named Billy with a liposomal-CBD injection in a pre-clinical trial. The therapy provided relief to the goat, which had neurological deficits and hind-limb paralysis. The treatment resulted in increased activity and improved quality of life for the goat. Innocan Pharmas liposomal-CBD injection allows for targeted delivery of CBD to specific body areas, enhancing efficacy and reducing side effects. The company aims to develop CBD-based therapeutics for various indications in both humans and animals. The article highlights the potential of Innocans technology to improve the lives of both humans and animals.
Customers
Innocan Pharma Announces 5000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets
growth-positive
Innocan Pharma Reports Annual 2022 Results with USD 2.6M in Revenue
Innocan Pharma Corporation, a pharmaceutical technology company, has reported its audited financial results for the year ended December 31, 2022. The company experienced significant revenue growth, with revenue for 2022 increasing to approximately $2.6 million from $196,000 in 2021. The increase in revenue is mainly attributed to the increased sales of Innocans subsidiary, BI Sky Global, which focuses on the development of beauty microbrands for platforms such as Amazon. The company also saw an increase in gross profit and a decrease in cash balance due to continued investments in strategic goals. Innocan has set ambitious goals for 2023, including expanding distribution agreements, growing online sales partnerships, and holding FDA Pre-IND meetings for veterinary and human applications of its drug delivery platform.
CustomersPartnersInvestment
Innocan Reports Novel Cannabinoid Delivery Platform Patent Application
Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Innocan Pharma Announces First Patent Grant in the United States
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
Innocan Pharma Provides Annual "State of the Business" Update
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
Canadian Securities Exchange Reports October 2022 Performance Figures
Innocan Pharma Goes Live with Priority(TM) ERP System
Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022
Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York
Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase
Innocan Pharma Provides an Operational Update
growth-positive
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
Innocan Pharma Corporation has announced positive results in a preclinical trial involving a dog with refractory epilepsy. The dog was treated with Innocan Pharmas LPT (CBD Loaded Liposome Platform) injections and experienced a significant reduction in seizures. The trial was conducted in collaboration with The Hebrew University. Innocans unique delivery method allows for the controlled release of CBD into the bloodstream, resulting in a more effective and continuous therapeutic effect. The company has a worldwide exclusive research and license agreement with The Hebrew University for the development of sustained release products of CBD. Innocan is focused on the development of drug delivery platforms containing CBD for various indications.
Customers
Future Markets Research Releases Commentary on InnoCan Pharma, a Leading Pharma-CBD Player Poised to Disrupt the Market
growth-positive
Sony Ex-VP Dr. Kenji Kitatani to Join Innocan Pharma's Advisory Committee
Innocan Pharma Corporation has announced the addition of Dr. Kenji Kitatani, a former Executive Officer of Sony Corporation, to its Advisory Committee. Dr. Kitatani will advise the company on its expansion into the Japanese and Asian markets. The popularity of CBD products in Japan is growing rapidly, and the Japanese market is keen to consume plant-based products. Industry forecasts expect Japan to become the second-largest medical CBD market in Asia by 2024. Innocan Pharma focuses on the development of drug delivery platforms containing CBD and is collaborating on a new exosome-based technology for CNS indications and the treatment of COVID-19. The company also has plans for a dermal product that integrates CBD with other pharmaceutical ingredients.
CustomersPartners
growth-positive
Innocan Announces the Execution of a Research & License Agreement with Ramot, the Technology Transfer Company of the Tel Aviv University for Cannabinoids Loaded Exosome Delivery Platform (CLX)
Innocan Pharma Corporation has signed a Research and License Agreement with Ramot, the Technology Transfer Company of Tel Aviv University. The agreement expands the research plan for the CBD Loaded Exosome Platform and grants Innocan Israel the exclusive license to commercialize the research results and products developed from the technology. The Company will fund the work plan with an aggregate amount of US$1,177,200. The agreement represents a significant milestone in Innocans strategic plan and further advances the development and commercialization of their pharmaceutical inventory. The CLX platform, which utilizes exosomes loaded with cannabinoids, holds potential for tissue regeneration, anti-inflammatory properties, and targeted therapy. Innocan Pharma is collaborating with Tel Aviv University and The Hebrew University of Jerusalem on various CBD drug delivery platforms and products.
PartnersInvestment
growth-positive
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Corporation has announced a private placement of its common shares and warrants to institutional investors, raising approximately C$8.2 million in gross proceeds. The company will issue up to 9,679,000 common shares and common warrants at a combined purchase price of C$0.85 per share. Each common warrant will entitle the holder to purchase one common share at an exercise price of C$1.10 per share. The closing date of the private placement is expected to occur on or about October 13, 2021. The private placement is subject to customary closing conditions and regulatory approvals. Innocan Pharma Corporation focuses on the development of drug delivery platforms containing CBD.
Investment
growth-positive
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Innocan Pharma Corporation has announced its intention to enter into a full Research and License Agreement with Ramot, the Technology Transfer Company of Tel Aviv University. The agreement, once entered, will grant Innocan a worldwide exclusive license to advance and commercialize products developed from the CBD Loaded Exosomes platform. This collaboration serves as a significant milestone in Innocans strategic commercialization strategy. The project aims to develop a breakthrough technology platform that enables the delivery of cannabinoids by loading them on Exosomes to be delivered to a specific body organ. Innocan Pharma is a pharmaceutical tech company focusing on the development of drug delivery platforms containing CBD.
Partners
InnoCan Pharma Launches Trading on OTCQB Venture Market - VNExplorer
growth-positive
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Innocan Pharma Corporation provides an update on its pre-clinical studies and the development progress of its Liposome/CBD delivery platform. The studies are led by researchers from The Hebrew University of Jerusalem and have shown positive results in animal trials, demonstrating the presence of CBD for extended periods. The company plans to initiate a third set of pre-clinical trials to examine additional indications for the platform. Innocan Pharma has a research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University, for the development of hydrogels containing CBD. The company is focused on the development of drug delivery platforms containing CBD for various applications.
InvestmentPartners
growth-positive
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Innocan Pharma Corporation has filed a patent application for its topical composition for hair loss treatment. The application claims several compositions for topical administration comprising cannabinoid for the treatment and prevention of hair loss. The global hair loss product market is growing, and Innocan aims to become a leading player in the dermatological arena. Studies have shown that the endocannabinoid system (ECS) plays a key role in hair follicle cell growth. According to a research article, a study using a once daily topical Cannabidiol (CBD) showed a statistically significant 93.5% increase in hair growth after six months. The global hair loss and growth treatments products market was valued at $3.1 billion USD in 2020 and is expected to reach $4.6 billion USD by 2026.
CustomersInvestment
growth-positive
Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study
Innocan Pharma Corporation has completed a cosmetic clinical study of its SHIR® CBD+ ANTI-AGING SLEEPING MASK. The study showed that women who tested the product experienced a reduction in the appearance of their lines and wrinkles by up to 28.8% in as little as 4 weeks. The results were extremely positive, with 90.5% of participants expressing that they would recommend the product to a friend and would like to buy it. The study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal. Innocan Pharmas skincare brand is created with a pharma approach and delivers safe and long-term effective results.
Customers
growth-positive
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Innocan Pharma Corporation has announced the addition of Izhar Shay, Israels former Minister of Science and Technology, and a leading Venture Capitalist, to its Advisory Committee. This addition is seen as a major indicator of the companys aspirations to reach global markets. Innocan Pharma focuses on the development of drug delivery platforms combining cannabidiol (CBD). They are collaborating with Ramot, the commercial arm of the Tel Aviv University, on an exosome-based technology that targets CNS indications and the COVID-19 Coronavirus using CBD. Innocan Pharma also has a license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome. The company is also working on dermal products and the development and sale of CBD-integrated pharmaceuticals.
Management Changes
growth-positive
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Innocan Pharma Corporation has filed an international patent application for a topical composition for the treatment of diabetic symptoms. The patent application includes several compositions for topical administration that contain cannabinoids for the treatment of diabetic-related conditions. The company aims to enhance blood flow to peripheral areas in patients suffering from diabetes symptoms. The global market for creams and lotions for diabetic foot care is expected to grow at a CAGR of 7.7% during the forecasted period of 2020-2029. Innocan is expanding its intellectual property portfolio of cannabis-based products to address inflammatory indications with unmet medical needs. The company now holds 12 patents and plans to file more patents in the future.
CustomersInvestment
growth-positive
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Innocan Pharma Corporation has signed an exclusive distribution agreement with Health Investment Group S.A. for the distribution of its SHIR and Relief & Go brands in Poland. The agreement will allow Innocan to tap into Polands rapidly growing luxury cosmetics and perfumes market, which is projected to exceed EURO 221 million by 2025. Additionally, the Polish market for hemp and CBD-derived products is expected to reach a total value of 1 billion EURO by 2025. Health Investment Group S.A., part of the IPS Holding Group, will distribute Innocans brands among pharmacies, pharmaceutical wholesalers, and selected retail chains in Poland.
PartnersCustomers
growth-positive
This Top Health-Tech Executive joins the CBD Pharma Industry and Boosts Shareholder Confidence
InnoCan Pharma, a Canadian-Israeli biotech company, has experienced growth and success in the pharmaceutical industry. The company focuses on developing smart delivery platforms with CBD-loaded combinations for various medical conditions. InnoCan has a strong management team and strategic partnerships with prestigious research institutions in Israel. They have recently added healthtech executive Peter Bloch to their team. Bloch has extensive experience in pharmaceutical development and has played a key role in the companys expansion efforts. InnoCan has obtained regulatory approvals and signed distribution agreements in Europe, Canada, and the United States. The company is listed on multiple stock exchanges and had a successful IPO in June 2020. InnoCan aims to become a leader in the biotech industry and is poised for further growth.
InvestmentPartners
growth-positive
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Innocan Pharma Corporation has completed a cosmetic clinical study of SHIR CBD Eye Serum, showing positive results in reducing eye bags. The study was conducted by an independent lab and the findings were consistent with industry standards. Additionally, Innocan has signed an agreement with Brandzon Co Ltd to establish a Joint Venture for marketing and sales of skincare and body care products. Innocan is a pharmaceutical tech company focused on developing drug delivery platforms containing CBD, including a new exosome-based technology for CNS indications and COVID-19. They have also signed a license agreement with The Hebrew University of Jerusalem for a unique-controlled release liposome platform. The company plans to test these platforms on various indications and develop CBD-integrated pharmaceuticals.
CustomersPartners
growth-positive
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Innocan Pharma Corporation has filed an international patent application for a cannabis-based Vaginal Moisturizer and Lubricant Treatment. The company aims to alleviate vaginal dryness and vaginal atrophy by developing a composition that includes cannabinoids, phytoestrogen, and hyaluronic acid. The market for vaginal moisturizers and lubricants is expected to grow from $2.15 billion in 2021 to $3.14 billion by 2026. Innocan Pharma sees this as a major achievement and an opportunity to expand its intellectual property portfolio. The company focuses on the development of drug delivery platforms combining CBD and aims to address inflammatory indications with unmet medical needs. Innocan Pharma is also collaborating on a CBD-loaded exosome-based technology for CNS indications and COVID-19 using CBD.
CustomersExpand
growth-positive
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Innocan Pharma Corporation has announced positive results from a recent study on mice, which demonstrated a prolonged release of cannabidiol (CBD) into the animals bloodstream for at least 7 weeks following local injections. The study was led by researchers from The Hebrew University of Jerusalem and utilized Innocans licensed CBD-loaded liposome platform technology. The company believes these results are encouraging and may open the door to a wide range of therapeutic possibilities, particularly in the treatment of conditions related to the central nervous system. Innocan Pharma has a research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, for the development of CBD-containing hydrogels. The company is focused on the development of various drug delivery platforms containing CBD.
Partners
growth-positive
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Innocan Pharma Corporation has announced the results of a recent study conducted in mice using its licensed CBD-loaded liposome platform technology. The study demonstrated a prolonged release of cannabidiol (CBD) into the bloodstream for at least 50 days following two injections. This is significant compared to other intake methods, such as oral or inhalation, which only result in CBD remaining in the bloodstream for a maximum of 36 hours. The results open up possibilities for various therapeutic applications. Innocan Israel, a subsidiary of the company, has entered into an exclusive research and license agreement with Yissum Research and Development Company for the development of hydrogels containing CBD-loaded liposomes. The technology has potential applications in epilepsy, pain relief, inflammation, and central nervous system disorders.
PartnersInvestment
growth-positive
Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Innocan Pharma Corporation has retained Lytham Partners to lead an investor relations and shareholder communication program. Lytham Partners will work with Innocan to communicate their value to the institutional investment community, particularly in the United States. Innocan Pharma focuses on the development of drug delivery platforms combining CBD and has collaborated with Ramot at Tel Aviv University on an exosome-based technology for CNS indications and COVID-19. They have also signed a worldwide exclusive license agreement with Yissum to develop a CBD drug delivery platform based on a unique-controlled release liposome. Innocan is also working on dermal products and the development and sale of CBD-integrated pharmaceuticals.
PartnersInvestment
growth-positive
Innocan Pharma Announces Trading on the OTCQB Venture Market and DTC Eligibility of Its Common Shares in the United States
Innocan Pharma Corporation announces that it is currently trading on the OTCQB Venture Market and is eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the United States. This provides the company with increased access to investors and a broader shareholder base. Innocan Pharmas common shares will continue to trade on the Canadian Securities Exchange (CSE) and the Frankfurt Stock Exchange. The OTCQB quality standards and DTC eligibility improve transparency and the trading experience for investors. Trading on the OTCQB Venture Market has no impact on existing Innocan Pharma common shares trading on the CSE.
Public Trading
growth-positive
Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France
Innocan Pharma Corporation has signed a wide-scope commercial distribution agreement with Polyflame Europe. Polyflame Europe will have the exclusive right to distribute Innocans SHIR and Relief & Go brands in France. The agreement is expected to contribute to Innocans exponential growth strategy and Polyflames Health and Beauty market strategy. The global CBD skin care market is projected to reach USD 1.7 billion by 2025. Polyflame Europe is a key European player in the import and distribution of regulated products. Innocan Pharma and SHIR aim to become market leaders in European countries, including France.
Partners
growth-positive
Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee
Innocan Pharma Corporation has added Richard Serbin to its Advisory Committee. Serbin, a regulation attorney, patent attorney, and pharmacist, brings extensive experience in the pharmaceutical industry and FDA regulations. His addition is expected to contribute to Innocans growth strategy and the advancement of therapeutic opportunities. The company focuses on developing drug delivery platforms combining cannabidiol (CBD) and is collaborating with Ramot at Tel Aviv University on an exosome-based technology targeting CNS indications and COVID-19. Innocan also signed a worldwide exclusive license agreement with Yissum to develop a CBD drug delivery platform based on a unique-controlled release liposome. The company is working on various CBD-integrated pharmaceuticals and dermal products. The founders and officers of Innocan have successful track records in the pharmaceutical and technology sectors.
PartnersManagement Changes
growth-positive
Leading American Dermatologist Dr. Mitchell Kline to Join Innocan Pharma's Scientific Advisory Committee
Innocan Pharma Corporation has announced the addition of Dr. Mitchell Kline to its Scientific Advisory Committee. Dr. Kline, a board-certified, fellowship-trained surgical and clinical dermatologist, will serve as an active member of Innocans R&D team. His extensive experience in researching and treating different skin conditions will be used to further develop Innocans derma cosmetic line. Innocan is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (CBD).
Management ChangesExpand
growth-positive
Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021
Innocan Pharma Corporation has received proceeds of approximately CDN $3.1M from the exercise of common share purchase warrants. The exercise of the warrants indicates investor confidence in the company. The company plans to accelerate its CBD drug delivery platform programs with Tel Aviv University and the Hebrew University. Innocan Pharma is collaborating with Ramot at Tel Aviv University on an exosome-based technology that targets CNS indications and the COVID-19 Coronavirus using CBD. They have also signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome. Innocan Pharma is working on the development of a dermal product that integrates CBD with other pharmaceutical ingredients.
Investment
growth-positive
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment
Innocan Pharma Corporation has filed an international patent application for a novel cannabis-based Anti-itch treatment. The company believes that its expanding intellectual property portfolio of cannabis-based products will lead to breakthroughs in skin therapy and opportunities in inflammatory indications. They plan to launch the Anti-itch Spray in the EU and US markets following a clinical study. Innocan Pharma focuses on the development of drug delivery platforms combining cannabidiol (CBD) and has collaborations with Tel Aviv University and the Hebrew University of Jerusalem. They are working on various CBD-integrated pharmaceuticals, including topical treatments for psoriasis symptoms and relief of muscle and rheumatic pain.
CustomersInvestment
growth-positive
Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform
Innocan Pharma Corporation has completed its first full-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States. The company has also launched its US Commercial Website, which will enable it to deliver products to the US market. Innocan has set agreements with world-leading companies for fulfillment, logistics, and service required to support the activities on the website. The launch of the website is seen as a major milestone and a great opportunity for Innocan to start with B2C operation that will secure a new and sustainable source of income for the company. Tamar InnoVest Limited has exercised warrants resulting in the issuance of common shares in the capital of the company.
CustomersPartners
N/A
https://www.bloomberg.com/press-releases/2021-01-28/innocan-pharma-announces-proceeds-of-cdn-1-8m-from-the-exercise-of-warrants-since-december-1-2020
The article is about Bloomberg Daybreak, a news program that provides listeners with economic, business, market, and global news.
growth-positive
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions
Innocan Pharma Corporation has successfully demonstrated the manufacturing of CBD-loaded Liposomes under aseptic conditions in collaboration with the Hebrew University of Jerusalem. This achievement allows for animal and human studies, bringing the product closer to the marketplace. The previous studies showed prolonged release of cannabidiol into the blood of mice and rats for up to three weeks. The results suggest that Innocans CBD-loaded Liposomes could provide pain relief and other therapeutic benefits. The company is focused on developing drug delivery platforms containing CBD and has collaborations for exosome-based technology and a unique-controlled release liposome platform. Innocan plans to test these platforms on various indications, including lung infections, psoriasis symptoms, and muscle and rheumatic pain.
InvestmentPartnersExpand
growth-positive
Innocan Pharma Successfully Completes Large Scale Production of Exosomes
Innocan Pharma Corporation has successfully completed a large-scale production of exosomes, a significant milestone in the development of its CBD Loaded Exosome (CLX) Therapy. The company produced trillions of exosomes in a short period of time, demonstrating its capability for economic large-scale production. This achievement will pave the way for larger tests and studies. Innocan Pharma is one of the few public companies in the exosomes science field. The CLX Therapy, developed in collaboration with Tel Aviv University, aims to target coronavirus infected lung cells and central nervous system diseases using CBD. The therapy combines the cell healing properties of exosomes with the anti-inflammatory properties of CBD. Innocan Pharma also issued 1,700,000 common shares to a third-party consultant. The company focuses on the development of drug delivery platforms using CBD.
InvestmentPartners
growth-positive
Innocan Pharma Announces the Launch of Its Commercial Website
Innocan Pharma Corporation has announced the launch of its commercial web-platform, shop.innocanpharma.com. The website aims to provide a user-friendly experience for consumers to browse and purchase products. Innocan Pharma has signed agreements with leading companies for fulfillment, logistics, and service of the website. Brandzon Co Ltd. will handle the online product distribution. The launch of the web-platform is seen as a major milestone for Innocan Pharma, as it marks the start of its B2C operation and a new source of income for the company. Innocan Pharma focuses on the development of drug delivery platforms combining cannabidiol (CBD) and has collaborations with Tel Aviv University and the Hebrew University of Jerusalem for the development of CBD-based products targeting various indications.
CustomersPartners
InnoCan Pharma announces the closing of its C$2.4M private placement
Innocan Pharma completes its first European cosmetics, topicals production and begins US manufacturing
growth-positive
Innocan Pharma Completes Its Trademark Registration in the EU, UK and Switzerland
Innocan Pharma Corporation has completed the registration of its trademarks in the EU, UK, and Switzerland. The trademarks represent Innocans OTC and derma cosmetic brand products that were recently launched in the German and UK markets. The company is excited to have a Registered Trademark for its brands, which will allow it to initiate the sales effort in the EU, UK, and Switzerland. Innocan is a pharmaceutical tech company that focuses on the development of drug delivery platforms combining cannabidiol (CBD). They are collaborating on a new exosome-based technology that targets CNS indications and the COVID-19 Corona Virus using CBD. Innocan also plans to develop a CBD drug delivery platform based on a unique-controlled release liposome and a dermal product that integrates CBD with other pharmaceutical ingredients.
Customers
growth-positive
Innocan Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage
Innocan Pharma Corporation has announced the launch of two therapeutic studies on small and large animals to examine the therapeutic efficacy of its CBD loaded liposome platform technology. The studies will be conducted by the Hebrew University of Jerusalem. The previous studies demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies aim to further explore the potential pain relief and other therapeutic benefits of Innocans CBD-loaded liposomes. Innocan Israel, a subsidiary of Innocan, has entered into an exclusive research and license agreement with Yissum Research and Development Company for the development of hydrogels containing CBD loaded liposomes. The company is focused on the development of various drug delivery platforms containing CBD for multiple indications.
PartnersInvestment
growth-positive
Innocan Enters Into Distribution Agreement to Sell its CBD Derma Cosmetic Products in Germany
Innocan Pharma Corporation has entered into a distribution agreement with iAmHealth Distribution UG to sell its SHIR Beauty and Relief & Go product lines in Germany. The agreement allows iAmHealth to distribute Innocans cosmetic CBD products in Germany on a non-exclusive basis. The partnership aims to provide a premier distribution channel for Innocans product lines in Germany.
Partners
growth-positive
Innocan Pharma's Relief & Go CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union
Innocan Pharma Corporation has announced that its R&G Relief & Go™ CBD Spray product has passed safety assessment requirements and received a Cosmetic Product Safety Report for marketing in the European Union. The companys subsidiary, Innocan Israel, has developed a unique formulation that combines CBD with active ingredients to aid in relaxation and recovery for sport-performing professionals. The CEO of Innocan expressed excitement about the accomplishment and the companys future. Innocan Israel is also collaborating on a new exosome-based technology for targeting CNS indications and the Covid-19 Corona Virus using CBD. The company has signed a license agreement with The Hebrew University of Jerusalem for a CBD drug delivery platform. Innocan Israel is also working on dermal products and topical treatments for various indications.
CustomersPartners
growth-positive
Innocan Pharma Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells
Innocan Pharma Corporation has published two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The articles highlight the potential therapeutic functions of mesenchymal stem cells (MSCs) and their exosomes in handling COVID-19, as well as the ability of CBD to reduce lung damage caused by cytokine storms. Innocan Israel, a subsidiary of the company, is developing a combined therapy using MSC-driven Exosome-based loaded with CBD to target COVID-19 and neurodegenerative diseases. The product aims to enhance the bodys ability to fight against the direct damage and cytokine storm caused by the virus. Innocan is a pharmaceutical tech company focused on developing drug delivery platforms containing CBD.
PartnersInvestment
growth-positive
Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum
Innocan Pharma Corporation has completed a cosmetic clinical study on 20 volunteers, demonstrating a 90-95% reduction in facial skin wrinkles after using its SHIR Premium CBD Facial Serum. The study was conducted by UPTEC, an independent lab, and the results were consistent with industry standards. The combination of active ingredients and CBD in the serum led to significant improvements in facial skin. The high satisfaction of the study participants indicates a potential market for Innocans skincare products and the opportunity for market penetration. Innocan Pharma Corporation focuses on the development of drug delivery platforms containing CBD and collaborates with research institutions to explore the use of CBD in treating various indications.
Customers
growth-positive
Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD
Innocan Pharma Corporation has announced that an animal study on mice demonstrated a prolonged release of Cannabidiol (CBD) into the blood for at least three weeks after one administration. The study was conducted by The Hebrew University of Jerusalem, based on Innocans licensed CBD loaded liposome platform technology (LPT) for injectable CBD. Innocan Israel, a subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem.
PartnersExpand
growth-positive
Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration
Innocan Pharma Corporation has completed a cosmetic clinical study on the impact of its SHIR Premium CBD Facial Serum on skin hydration. The study showed significant increases in skin hydration after the application of the serum. The company aims to bring a trustworthy product to the market that will set a new industry standard. Innocan Pharma Corporation is a pharmaceutical tech company focused on the development of drug delivery platforms containing CBD. They have collaborated with Ramot at Tel Aviv University on an exosome-based technology that targets CNS indications and the Covid-19 Corona Virus using CBD. The company has also signed a license agreement with Yissum to develop a CBD drug delivery platform based on a unique-controlled release liposome.
CustomersPartners
Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland
growth-positive
Innocan Engages Endless Sky to Manufacture and Distribute Innocan's CBD Cosmetic Products in Canada
Innocan Pharma Corporation has announced a manufacturing and distribution agreement with Endless Sky Incorporated (ESI), a large scale Cannabis extractor based in Canada. Under the agreement, ESI will be the exclusive distributor of Innocans CBD products in Canada and will manufacture these products at its Health Canada licensed facility. The agreement is dependent on ESI receiving Health Canadas approval by December 31, 2020. The deal is set for a term of 12 months and will be extended based on ESI achieving minimum sales targets.
Partners
growth-positive
Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA
Innocan Pharma Corporation has received FDA approval to market its pain relief spray product in the USA. The product contains a combination of Magnesium oil, Methyl salicylate, Menthol, and CBD, and is designed to target pain-related muscle and joint pain. The approval represents the companys ability to develop breakthrough technologies and create new CBD-based products for the growing pain relief market. Chronic pain affects approximately 1.5 billion people worldwide, and the chronic pain treatment market is projected to reach US $105.9 billion by 2024. Innocan Pharma focuses on the development of drug delivery platforms combining CBD and is collaborating on an exosome-based technology for CNS indications and COVID-19. The company also has a license agreement with the Hebrew University of Jerusalem for a CBD drug delivery platform based on a unique-controlled release Liposome.
Customers
growth-positive
InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments
InnoCan Pharma Corporation has announced its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes. Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry. The collaboration will allow InnoCan Pharma to focus on exosome technology production/loading while Recipharm will handle the analysis work. The development of the CLX-CBD loaded Exosome is seen as challenging but holding huge potential. InnoCan Pharma and Recipharm are working closely on the development of this technology. InnoCan Pharma is a pharmaceutical tech company that focuses on the development of drug delivery platforms combining CBD with other pharmaceutical ingredients. Recipharm offers a wide range of services in pharmaceutical development and manufacturing.
Partners
https://www.marketwatch.com/press-release/innocan-pharma-announces-mackie-researchs-institutional-sales-group-issues-enterprise-publication-on-the-company-2020-06-22
growth-positive
Cannabis-infused treatment for Covid-19 under development
InnoCan Pharma Israel is collaborating with Tel Aviv University tech-transfer company Ramot to develop an exosome-based technology targeting Covid-19 and other lung inflammations. The product, expected to be administered by inhalation, will be tested against various lung infections. The collaboration is based on the research work of Prof. Daniel Offen, a leading researcher in neuroscience and exosome technology. InnoCan has agreed to fund the research with approximately $450,000 for the first stage. The company recently closed a $5.1 million prospectus offering to help finance the research.
PartnersInvestment
growth-positive
Israeli cannabis company InnoCan raises $3.7 million
InnoCan Pharma Ltd., an Israel-based company, has closed a $3.7 million prospectus offering of units on the Canadian Securities Exchange. The funds raised will be used for research and product development, sales and marketing, and general and administrative expenses. InnoCan focuses on the development of drug delivery platforms combining CBD with other pharmaceutical ingredients. The company is collaborating with Tel Aviv University on the development of an exosome-based technology for central nervous system indications and COVID-19. InnoCan has also entered into a research and license agreement with Yissum Research and Development Company to develop a CBD drug delivery platform. Prior to its IPO, InnoCan raised $4.4 million, with investments from Gibraltar-registered Solsken limited and a crowdfunding campaign.
Investment
Innocan Pharma launches Derma CBD line in Europe
growth-positive
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Psoriasis Treatment
Innocan Pharma Corporation, a pharmaceutical tech company, has filed an international patent application for a novel cannabis-based psoriasis treatment. The global psoriasis drugs market is projected to reach USD 39.00 Billion by 2027. Innocan believes that its expanding intellectual property portfolio of cannabis-based products can lead to breakthroughs in pain therapy and opportunities in inflammatory indications. The company is collaborating with Ramot at Tel Aviv University to develop an exosome-based technology for central nervous system indications and COVID-19. Innocan has also entered into a research and license agreement with Yissum Research and Development Company to develop a CBD drug delivery platform. The company is focused on developing dermal products and CBD-integrated pharmaceuticals for various indications.
Customers
growth-positive
Innocan Pharma Announces up to $10 Million Public Offering of Units
Innocan Pharma Corporation has filed a preliminary short form prospectus for a marketed public offering of units for gross proceeds of up to $10,000,000. The offering is being led by Mackie Research Capital Corporation and Canaccord Genuity Corp. The net proceeds will be used for research and product development expenses, sales and marketing expenses, operating expenses, and general corporate purposes. The closing of the offering is expected to be on or about the week of May 28, 2020.
InvestmentPublic Trading
growth-positive
InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
InnoCan Pharma Corporation has entered into a sponsored research agreement with Ramot at Tel Aviv University to develop a novel approach to treat COVID-19 using CBD-loaded Exosomes. The collaboration aims to develop a cell therapy product that combines the anti-inflammatory properties of CBD with the healing properties of Exosomes. The research results may also be beneficial for other CNS indications. InnoCan Pharma has agreed to fund the research with an aggregate amount of approximately US $450,000 for the first stage. The company also has the option to receive an exclusive worldwide royalty-bearing license to Ramots background technology and research results. InnoCan Pharma is listed on the Frankfurt Stock Exchange under the trading symbol FRA: IP4.
PartnersInvestment
InnoCan Pharma's CBD-based Derma Cosmetic products to be sold in the UK and Ireland
growth-positive
InnoCan Announces It Has Executed A Research & License Agreement With The Commercial Arm Of The Hebrew University
InnoCan Pharma Corporation has signed a Research and License Agreement with Yissum Research and Development Company to extend their previous agreement. The new agreement finalizes the terms of contracts, including the scope of business and the terms of license. It also includes a new research work plan for the next 18 months, with a cost of approximately US$1.6 million. The agreement grants InnoCan Israel a worldwide exclusive license to commercialize the research results and the products developed from the technology. The project aims to develop a technology platform for the delivery of cannabinoids by injection of hydrogel-cannabinoid-loaded liposomes. The use of this technology can have various applications in the development of different cannabinoids. InnoCan Pharma Corporation focuses on the research, development, marketing, distribution, and sales of CBD products.
Partners
InnoCan Pharma's CBD-loaded liposomal technology achieves positive test results
growth-positive
InnoCan Pharma Announces Patent Application to Enable CBD Targeted Injections
InnoCan Pharma Corporation has announced that Yissum Research and Development Company, the commercial arm of Hebrew University (Jerusalem), has filed a provisional patent for a unique cannabinoids loaded liposome platform technology. This was developed under the Companys funded research agreement, the Yissum Agreement. The technology is aimed at enabling the delivery of cannabinoids by injection of hydrogel-cannabinoid-loaded liposomes into the blood stream or to a specific body part. The use of the technology is versatile and may be tailored to the development of different cannabinoids.
Partners
growth-positive
Cannabis Company InnoCan Lists on the Canadian Securities Exchange
InnoCan Pharma Ltd., an early stage company developing cannabinoid-based drugs, raised $1.5 million in an IPO on the Canadian Securities Exchange. The company listed 4% of its shares at a valuation of $12.08 million. The funds raised will go to the companys coffers. InnoCan has raised a total of $4.4 million to date, with investments from Solsken limited and a crowdfunding campaign on Pipelbiz. Listing in Canada will help InnoCan reach a wider variety of investors.
InvestmentPublic Trading
growth-positive
OTC drugs for psoriasis and pain to be enhanced with cannabis
InnoCan, a pharmaceutical company, is developing an over-the-counter topical treatment for psoriasis and pain that combines proven drugs with cannabis compounds CBD and hemp oil. The company raised nearly ₪3 million in equity on an Israeli crowdfunding platform and plans to go public on the Canadian exchange later this year. InnoCans go-to-market strategy is to license the formulations to strategic partners or collaborate with local distributors. The company aims to be a leader in the fast-growing cannabis industry.
InvestmentPublic Trading
growth-positive
Israeli cannabis startup InnoCan recruits 500 investors online
Israeli startup InnoCan Pharma has completed a NIS 3 million ($800,000) financing round. The round, which is the first of its kind in Israel, involved 500 investors who bought shares in the company through the Pipelbiz crowdfunding platform. InnoCan Pharma develops drugs containing material produced from cannabis for skin diseases. The company aims to have the finished product defined as a drug by the regulator through an abbreviated process designed for over-the-counter dermatological products.
Investment
growth-positive
Former Teva Israel CEO founds crowdfunded cannabis co
Ron Mayron, former CEO of Teva Israel, has founded InnoCan Pharma, a cannabis company. The company plans to raise money through a crowdfunding platform called Pipelbiz. InnoCan Pharma develops drugs for skin diseases using material produced from the cannabis plant. The goal is to have the finished products classified as a drug for regulatory purposes. The company aims to utilize a shortened track designed for over-the-counter dermatological products. The announcement was made on July 10, 2018.
InvestmentExpand
InnoCan Pharma Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 15 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
InnoCan Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515732881 |
| Crunchbase | innocan-pharma |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-03-28T00:00:00.000Z |
| Created | 2018-07-24T00:00:00.000Z |
| Status detail | Public on CSE on Sep, 2019;Public on OTCQB on Aug, 2021; |